Solvemed announced Tuesday that it raised $3.5 million to help build out an artificial intelligence-based ocular biomarker engine that it hopes will enable portable diagnosis of neurological diseases using the eye as a window into the brain.
Investors included European and US venture capital firms such as Atmos, APEX, Tensor, Preface and Techni, alongside Sunfish Partners, which had also contributed at the pre-seed stage in 2020.
Solvemed develops digital biomarkers for the clinical evaluation and monitoring of neurological conditions, with a focus on neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease and multiple sclerosis.
According to Solvemed, its technology means health professionals will be able to dispense with legacy devices and opt instead for a "single, high-precision data capture and image processing platform, which will allow for expanded clinical examination and at-home monitoring.
According to Solvemed, its technology means health professionals will be able to dispense with legacy devices and opt instead for a "single, high-precision data capture and image processing platform, which will allow for expanded clinical examination and at-home monitoring.
Proceeds will be used to expand Solvemed's technology and clinical work, and will help fund the company through initial regulatory approvals in Europe and the US," the start-up said.”
According to Solvemed, its technology means health professionals will be able to dispense with legacy de
Meanwhile, Gordon Euller, general partner at APEX Ventures, remarked "we believe that their solution is digitally transforming a standard test in every physical examination of a patient.
Use of ocular biomarkers as a potential tool for early diagnosis of certain types of neurodegenerative diseases has been showing a lot of promise over the last several years," noted Dominik Andrzejczuk, managing director of Atmos Ventures, adding that Solvemed's technology "enables the capturing of these biomarkers to be done inexpensively and at scale, giving the company a competitive advantage in both technology and data acquisition.
This leads to standardisation and opens new ways to diagnose diseases early and monitor these."
Meanwhile, Gordon Euller, general partner at APEX Ventures, remarked "we believe that their solution is digitally transforming a standard test in every physical examination of a patient.
Use of ocular biomarkers:
Meanwhile, Gordon Euller, general partner at APEX Ventures, remarked "we believe that their solution is digitally transforming a standard test in every physical examination of a patient.
We guarantee no spam . One high-quality email per month packed with valuable updates, exciting news. Join now!